Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767486 | 0.85 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL5144794 | 0.84 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL5765502 | 0.84 | TLR8 (0.41) | TLR8TLR7HDAC6 | |
| SCHEMBL2399819 | 0.84 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL5765605 | 0.82 | HPGDS (0.40) | TLR8TLR7 | |
| SCHEMBL5763743 | 0.81 | TLR8 (0.39) | TLR8TLR7POLB | |
| SCHEMBL1528024 | 0.80 | TLR8 (0.58) | TLR8TLR7ALDH1A1 | |
| SCHEMBL10467760 | 0.79 | POLB (0.42) | TLR8CYP3A4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL5531698 | 0.77 | DHFR (0.44) | TLR8TLR7CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL5090104 | 0.77 | NCF1 (0.36) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148232-B2 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1380587-B1 | Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026943-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-03 | — | — | US | disclosed |
| US-6809203-B2 | IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6703402-B2 | IMMUNOMODULATORS; INDUCERS OF CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON AND/OR TUMOR NECROSIS FACTOR; ANTITUMOR AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-03-09 | — | — | US | disclosed |
| EP-1380587-A2 | Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof | 3M Innovative Properties Company (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677334-B2 | IMMUNOMODULATORS, INDUCE CYTOKINE BIOSYNTHESIS, AND ANTINEOPLASTIC AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-6627638-B2 | Viricides, anticarcinogneic agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-30 | — | — | US | disclosed |
| EP-1100802-B1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-06 | — | — | US | disclosed |
| US-6440992-B1 | ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-6323200-B1 | THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. | 3M INNOVATIVE PROPERTIES COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885CYP3A4 921/4885 |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885CYP3A4 921/4885 |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885CYP3A4 921/4885 |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885CYP3A4 921/4885 |
| US-20050026943-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, IL2, IRF3 | TLR8 179/4885TLR7 68/4885CYP3A4 703/4885 |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885CYP3A4 921/4885 |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885CYP3A4 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.